Abstract Glioblastoma (GBM) patients often face cognitive impairment, which may limit their capacity to comprehend complex trial information, particularly regarding genomic analyses and incidental findings. We analyzed consent forms from a genomic study, including 108 newly diagnosed grade 4 GBM patients in the Danish Glioblastoma Cohort (2016–2019) undergoing whole-exome sequencing. Of 110 patients, 108 (98.2%) consented. Preferences for incidental findings varied: 31% chose no information, 22% actionable findings only, and 42% all information. Despite the complexity, participation was high, suggesting that GBM patients are willing and able to participate in genomic research when flexible consent options are offered.
Sjøstrøm et al. (Wed,) studied this question.